Polymorphism of tandem repeat in promoter of 5‐lipoxygenase in ASA‐intolerant asthma: a positive association with airway hyperresponsiveness

Background:  5‐Lipooxygenase (ALOX5) and 5‐lipoxygenase‐activating protein (ALOX5AP) are known as key enzymes in cysteinyl‐leukotriene (cys‐LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)‐intolerant asthma (AIA). To date, studies of the promoter region of ALOX5 gene has revealed the potential influence of a variable number of tandem repeats of a Sp1‐ and Egr1‐binding motif, on the transcription rate.

[1]  R. Dixon,et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.

[2]  A. Ford-hutchinson,et al.  Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. , 1992, The American review of respiratory disease.

[3]  E. Middleton,et al.  Allergy, principles and practice , 1978 .

[4]  E. Silverman,et al.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. , 1997, The Journal of clinical investigation.

[5]  D. Stevenson,et al.  Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. , 2003, The Journal of allergy and clinical immunology.

[6]  C. Funk,et al.  Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene , 1994, Nature.

[7]  T. Koshino,et al.  Novel polymorphism of the 5-lipoxygenase activating protein (FLAP) promoter gene associated with asthma. , 1999, Molecular cell biology research communications : MCBRC.

[8]  T. Koshino,et al.  Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein mRNAs in the peripheral blood leukocytes of asthmatics. , 1998, Biochemical and biophysical research communications.

[9]  I. Sayers,et al.  Promoter polymorphism in the 5‐lipoxygenase (ALOX5) and 5‐lipoxygenase‐activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  L. Dubé,et al.  Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. , 1998, American journal of respiratory and critical care medicine.

[11]  Jilly F. Evans,et al.  Identification and isolation of a membrane protein necessary for leukotriene production , 1990, Nature.

[12]  E. Israel,et al.  Treatment of asthma with drugs modifying the leukotriene pathway. , 1999, The New England journal of medicine.

[13]  T. Lee,et al.  Urinary leukotriene E4 in bronchial asthma. , 1992, The European respiratory journal.

[14]  B. Vargaftig,et al.  Leukotrienes mediate part of Ova-induced lung effects in mice via EGFR. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[15]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[16]  S. Holgate,et al.  Antileukotriene therapy. Future directions. , 2000, American journal of respiratory and critical care medicine.

[17]  E J Louis,et al.  An exact test for Hardy-Weinberg and multiple alleles. , 1987, Biometrics.

[18]  D. N. Landon,et al.  Synthesis of leukotriene B4, and prostanoids by human alveolar macrophages: analysis by gas chromatography/mass spectrometry. , 1984, Prostaglandins.

[19]  D. Stevenson,et al.  Aspirin-induced asthma: advances in pathogenesis and management. , 1999, The Journal of allergy and clinical immunology.

[20]  M. Peters-Golden,et al.  Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alveolar macrophages. , 1994, American journal of respiratory cell and molecular biology.

[21]  D. Munafo,et al.  Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3. , 1996, The Journal of clinical investigation.

[22]  P. Vickers,et al.  5-Lipoxygenase-activating protein (FLAP). , 1995, Journal of lipid mediators and cell signalling.

[23]  H. Shin,et al.  Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase , 2004, Human Genetics.

[24]  I. Hall,et al.  5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists , 2002, European Journal of Clinical Pharmacology.

[25]  L. Dubé,et al.  Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial , 1996 .